Brief: Actinium Pharmaceuticals Inc To Highlight IOMAB-B Pivotal Phase 3 Sierra Trial Data At The Transplantation & Cellular Therapy Tandem Meetings Of Astct And Cibmtr
19/04/2022 12:33
April 19 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS, INC. TO HIGHLIGHT IOMAB-B
PIVOTAL
PHASE 3 SIERRA TRIAL DATA AT THE TRANSPLANTATION & CELLULAR
THERAPY TANDEM MEETINGS OF ASTCT AND CIBMTR
Source text for Eikon: ID:nPn3Ywbvta
Further company coverage: ATNM.A
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities